Clinical Trial

A Study of Treatment Patterns and Real-World Outcomes in IgA Nephropathy Patients in the United States

Completed
View on ClinicalTrials.gov →
Summary
The aim of this study was to characterize real-world treatment patterns, including therapy sequences, escalation, and duration, and treatment outcomes in IgA nephropathy (IgAN) patients in the United States (US). The study used data which has detailed information on renal biopsy and laboratory data, linked with medical and pharmacy claims.
Trial Details
NCT Number NCT07757048
Lead Sponsor Novartis Pharmaceuticals
Conditions IGA Nephropathy
Enrollment 6,286 participants
Start Date 2026-03-12
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-11